A study reported in the online PracticeUpdate journal Renal Cell Carcinoma this week shows aflibercept, a vascular endothelial growth factor receptor (VEGFR) inhibitor, prolongs progression-free survival in people with previously treated advanced clear cell renal cell carcinoma (ccRCC).

Patients with previously treated advanced or metastatic ccRCC were treated with one of two doses of aflibercept (1 mg/kg or 4 mg/kg) on day 1 of a 14-day cycle until progression of the disease. Hypertension, protein in the urine, and fatigue were the most prevalent adverse events. At 8 weeks, 61% of the 59 patients on the 4-mg/kg dose were progression-free.


The researchers suggest that aflibercept may be effective in the second-line treatment of ccRCC, and further research is warranted.

Read more here